A Non-Randomized, Open-Label, Single-Arm, Phase 2 Study of LY2875358 in Patients With MET Diagnostic Positive, Advanced Gastric Cancer

Trial Profile

A Non-Randomized, Open-Label, Single-Arm, Phase 2 Study of LY2875358 in Patients With MET Diagnostic Positive, Advanced Gastric Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Emibetuzumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Dec 2017 Primary endpoint (Progression Free Survival (PFS) Rate) has not been met as per the results published in the Cancer Chemotherapy and Pharmacology
    • 01 Dec 2017 Results assessing activity, safety and pharmacokinetics of emibetuzumab published in the Cancer Chemotherapy and Pharmacology
    • 09 Nov 2015 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top